Harbin-based pharmaceutical manufacturer selling generic drugs in China.
Harbin-based pharmaceutical manufacturer selling generic drugs in China.
Moat: none
Headquarters: Harbin, China · Employees: 2,350
Size Harbin Gloria Pharmaceuticals (002437.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $941M, the 2269th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.86 on 18 Nov 2026.
Performance Over six months the shares fell 9.2%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 15.6% over the last twelve months (peer median +2.4%); the operating margin is 13.0% (peer median 7.1%).
Valuation It trades at 2.8× enterprise value to sales against a peer median of 4.5× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.2 points above its cost of capital (7.7% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.90B | CN¥2.12B | CN¥2.42B | CN¥2.60B | CN¥3.07B |
| Revenue growth | — | -13% | -7% | -15% | — |
| Gross profit | CN¥915M | CN¥929M | CN¥1.27B | CN¥1.49B | CN¥2.32B |
| EBITDA | n/a | CN¥318M | CN¥312M | CN¥275M | CN¥230M |
| Net income | CN¥381M | CN¥377M | CN¥233M | CN¥120M | -CN¥291M |
| Free cash flow | CN¥246M | CN¥291M | CN¥360M | CN¥251M | CN¥245M |
| Capital expenditure | CN¥19.4M | CN¥23.8M | CN¥62.9M | CN¥29.6M | CN¥33.0M |
| Total debt | CN¥107M | CN¥136M | CN¥107M | CN¥675M | CN¥1.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002437.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | -9.4% | 11th highest of 21 |
| 6-month return | -9.2% | -22.0% | 6th highest of 21 |
| Distance from 52-week high | -43.9% | -46.9% | 10th highest of 21 |
| Revenue growth (TTM) | -15.6% | +2.4% | 7th lowest of 18 |
| Operating margin | 13.0% | 7.1% | 7th highest of 18 |
| EV / Sales | 2.8× | 4.5× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 7.7% | 9.1% | 6th least demanding of 12 |
| Growth delivered (Del g) | -6.9% | +7.8% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | +14.7 pp | +2.8 pp | 4th most demanding of 12 |
| ROIC minus cost of capital | +7.2 pp | -2.0 pp | 3rd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 1.3× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | 75.0× | 6.5% | -60.6% |